Choline metabolism is important for very low-density lipoprotein secretion, making this nutritional pathway an important contributor to hepatic lipid balance. The purpose of this study was to assess whether the cumulative effects of multiple single nucleotide polymorphisms (SNPs) across genes of choline/1-carbon metabolism and functionally related pathways increase susceptibility to developing hepatic steatosis. In biopsy-characterized cases of nonalcoholic fatty liver disease and controls, we assessed 260 SNPs across 21 genes in choline/1-carbon metabolism. When SNPs were examined individually, using logistic regression, we only identified a single SNP (PNPLA3 rs738409) that was significantly associated with severity of hepatic steatosis after adjusting for confounders and multiple comparisons (P‫.)20.0؍‬ However, when groupings of SNPs in similar metabolic pathways were defined using unsupervised hierarchical clustering, we identified groups of subjects with shared SNP signatures that were significantly correlated with steatosis burden (P‫.)2000.0؍‬ The lowest and highest steatosis clusters could also be differentiated by ethnicity. However, unique SNP patterns defined steatosis burden irrespective of ethnicity. Our results suggest that analysis of SNP patterns in genes of choline/1-carbon metabolism may be useful for prediction of severity of steatosis in specific subsets of people, and the metabolic inefficiencies caused by these SNPs should be examined
Nonalcoholic fatty liver disease (NAFLD) is a common disorder, affecting ϳ30% of people in the general population and up to 96% of obese individuals. It encompasses a spectrum from steatosis to advanced liver injury (1) . The prevalence of steatosis has increased in parallel to obesity and metabolic syndrome, and it is often a concurrent phenotype. Single nucleotide polymorphisms (SNPs) in several genes have been individually associated with steatosis, but these associations only explain a small percentage of the risk and often fail to be replicated (2) . It is unclear whether steatosis is a cause, predisposing factor, or consequence of metabolic disease, although many regard it as the hepatic manifestation of metabolic syndrome. In many cases, NAFLD maintains a benign course, but some individuals progress to fibrosis, cirrhosis, liver failure, and cancer (1) . Increasing evidence indicates that hepatocellular carcinoma (HCC) may be partially attributable to metabolic disease, suggesting common pathogenic mechanisms (3) . Improving our understanding of the factors that modify the risk of hepatic steatosis is of great value, from both metabolic and disease progression perspectives.
Steatosis occurs when there is an imbalance between the rate of formation of triglycerides in liver and the capacity to remove those triglycerides by oxidation or by secretion as lipoproteins. Many factors contribute to this imbalance (4) . Choline metabolism is one key mediator of hepatic lipid homeostasis and intersects with multiple pathways that also mediate deposition of lipids in the liver (Fig. 1) . Perturbations in choline/1-carbon metabolism that decrease the synthesis of phosphatidylcholine (PtdCho) reduce capacity to secrete very low density lipoprotein (VLDL) and thereby impair secretion of triglycerides from liver (5) . Humans eating choline-deficient diets, or fed parenterally with solutions low in choline, develop fatty liver, and specific SNPs in choline/1-carbon metabolism increase susceptibility (6 -9) . Recent evidence indicates that choline/ 1-carbon metabolism intersects with energy metabolism pathways (4) , suggesting that choline could be an important contributing factor in the metabolic imbalances associated with hepatic steatosis.
Because of the role of choline metabolism in mechanisms relevant to both hepatic lipid balance and obesity, we hypothesized that patterns of SNPs in genes that span choline/1-carbon metabolism and related pathways mediate susceptibility to steatosis (Fig. 1) . To identify this genetic signature for steatosis, we began with an assessment of individual SNP effects in biopsycharacterized hepatic steatosis case and control subjects with a comprehensive range of body weights. To investigate the contribution of the combined effects of multiple SNPs on severity of steatosis, we implemented a novel unsupervised hierarchical clustering approach to group subjects by shared genotypes and asked whether these SNP patterns in choline/1-carbon genes and functionally related pathways correlated with steatosis burden. Our findings suggest that the interaction of these genetic variants results in metabolic inefficiency due to alterations in protein function that cumulatively alters flux through metabolic pathways.
MATERIALS AND METHODS

Human subjects
The Duke University Health Systems NAFLD Clinical Database and Biorepository includes subjects (age Ն18) with risk factors for NAFLD who underwent clinical evaluation and standard of care percutaneous liver biopsy for assessment of this presumed diagnosis. Informed consent of participants and Duke Institutional Review Board approval for genetic analysis were obtained for the purpose of this study. Our study includes 446 subjects for whom both histological data and DNA were available. Of these subjects, 263 (63%) had biopsies due to metabolic or biochemical risk factors for NAFLD, and 183 (37%) had biopsies during bariatric surgery. The subjects who underwent bariatric surgery were typically not required to undergo weight-loss interventions prior to surgery. Any patient who reported alcohol consumption in excess of 20 g/d or had positive serologic studies for chronic viral hepatitis B or C was excluded. Demographic, anthropometric, and clinical data were obtained at the time of liver biopsy. Whole blood for serum, plasma, DNA, and RNA was collected at the time of liver biopsy. Laboratory studies (i.e., lipids, glucose, liver aminotransferases, and measures of liver synthetic function) were obtained within 6 mo of liver biopsy or 1-2 wk prior to bariatric surgery. The presence of diabetes mellitus was defined by known diagnosis in the medical record, use of any antidiabetic agent or insulin, fasting glucose value of Ն126 mg/dl, 2 h glucose tolerance test of Ն200 mg/dl, and/or a glycosylated hemoglobin value of Ͼ6.5%. All liver biopsies were reviewed and graded for steatosis according to the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) scoring system (10) .
Candidate gene selection and genotyping
Twenty-one candidate genes were identified for study: ATPbinding cassette, subfamily B (MDR/TAP), member 4 Figure 1 . Genes in choline/1-carbon metabolism and related pathways influence hepatic lipid balance. One factor that influences accumulation of fat in the liver is excess calorie intake, as fatty acids are taken up by the liver and glucose is converted to lipids in the liver. At the same time, lipids are secreted from the liver, mainly as very low density lipoproteins (VLDLs). The net balance between lipid inputs and outputs determines whether hepatic steatosis develops. Secretion of VLDL requires synthesis of a lipid envelope containing apoproteins and phosphatidylcholine (PtdCho). APOC3 is needed for apolipoprotein synthesis. PtdCho is formed from choline, or from methyl-groups in S-adenosylmethionine (AdoMet) that can be derived from choline or from 1-carbon pool (via methyl-tetrahydrofolate; MTHFR encodes for the enzyme that forms 5-methyl-terahydrofolate). Choline transport into the hepatocyte and then into the mitochondria is mediated by the gene product of SLC44A1. CHDH, BHMT, and PEMT are important genes for the pathway forming PtdCho. PtdCho can be used to make VLDL, or can be hydrolyzed in a pathway involving PNPLA3, or secreted in bile by a flippase encoded for by ABCB4. We found that SNP patterns across multiple genes, including ABCB4, APOC3, CHDH, PEMT, PNPLA3, MTHFR, and SLC44A1, were associated with hepatic steatosis burden.
(ABCB4), adiponectin (ADIPOQ), apolipoprotein C-III (APOC3), betaine-homocysteine methyltransferase (BHMT), cystathionine-␤ synthase (CBS), choline dehydrogenase (CHDH), choline kinase ␣ (CHKA), choline kinase ␤ (CHKB), fatty acid desaturase 2 (FADS2), methylenetetrahydrofolate desaturase 1 (MTHFD1), 5,10-methylenetetrahydrofolate reductase (MTHFR), 5-methyltetrahydrofolate-homocysteine methyltransferase (methionine synthase; MTR), phosphate cytidylyltransferase 1, choline, ␣ (PCYT1A), phosphate cytidylyltransferase 1, choline, ␤ (PCYT1B), phosphatidylethanolamine-N-methyltransferase (PEMT), patatin-like phospholipase domain containing 3 (PNPLA3), peroxisome proliferator-activated receptor ␥ (PPARG), stearoyl-CoA desaturase (SCD), serine hydroxymethyltransferase 1 (SHMT1), solute carrier family 44, member 1 (SLC44A1), and signal transducer and activator of transcription 3 (STAT3). Gene selection was based on the hypothesis that choline metabolism influences hepatic steatosis. Thus, selected genes are involved in choline/lipid metabolism and/or are involved in pathways believed to influence the pathophysiology of NAFLD and that intersect functionally with the 1-carbon pathway. (15) . Genotyping was initially conducted on the Illumina GoldenGate array. However, because of failures in that platform or design-related constraints, Sequenom and real-time PCR methods were also used. Methods and rationale for the use of these platforms are described in more detail below.
Oligo-specific extension-ligation assay 300 SNPs were genotyped with an Illumina GoldenGate array (13) at the University of North Carolina Mammalian Genotyping Core (Chapel Hill, NC, USA) with a design based on dbSNP reference SNP (rs) numbers from genome build 128 (NCBI Genome Build 36.1). The raw Illumina genotyping data were analyzed by GenomeStudio 2010 data analysis software (Illumina) for automated genotype calling. Parent/ child trios from the Centre d'Étude du Polymorphisme Humain (CEPH) pedigree were obtained from the Coriell Cell Repository (Camden, NJ, USA; http://ccr.coriell.org/) and were included on each plate, including one replicate sample. Quality control (QC) procedures were implemented as per standard Illumina procedures, with additional manual review of SNP clusters to ensure data integrity. Twenty-one SNPs did not pass QC, and 30 had a minor allele frequency of Ͻ1%, leaving 249 SNPs that were included in the analysis.
Matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) primer extension assay
A subset of SNPs (nϭ17) was assayed using a multiplexed MALDI-TOF primer extension assay (MassArray iPLEx Gold; Sequenom; ref. 14) per the manufacturer's instructions (David H. Murdock Research Institute, Genomics Core Facility, Kannapolis, NC, USA) for the following reasons: failure on the Illumina platform; SNPs could not be genotyped with Illumina due to design constraints; SNPs were believed to be tri-or tetra-allelic on newer versions of dbSNP but still passed the design score for Illumina (i.e., these were measured on both platforms); or SNPs were not included in the original Illumina design but were subsequently identified as having an important role in NAFLD. Primers were designed using the MassArray 4.0 assay designer software (Sequenom). The assay was validated using samples from the Coriell Cell Repository and 2 samples from the population being studied. Coriell samples were also run with each assay (6 samples from various ancestries, run in replicates). Genotyping data were generated by MassArray Typer 4.0 (Sequenom). Genotyping quality was assured by manual inspection. Out of all the putative trior tetra-allelic SNPs, a third allele was found for two SNPs, but each of these appeared in only one subject. Inspection of these data showed comparable genotype calls (except at the two loci with a third allele). This validates our multiplatform approach. Also, because of the very small incidence of additional alleles and the superior call rate with Illumina, all duplicated SNP data (nϭ3) were used from the Illumina platform. One SNP failed on this platform, and 3 had minor allele frequencies of Ͻ1%, leaving 10 SNPs that were included in the analysis.
Real-time PCR genotyping for PEMT rs12325817
This SNP was essential in our analysis due to its relevance to choline deficiency-mediated fatty liver in humans, but did not pass the design score for the Illumina or Sequenom assays. We previously developed and validated a SYBR green-based allele-specific PCR method to genotype this SNP (15) . The same method was utilized, with the exception that it was optimized for real-time PCR. Forward primers specific to each allele were designed so that the SNP is located at the 3=-end of the priming sequence (forward for C allele: 5=-CCTGGA-CAACATGGTGACACTCC-3=; forward for G allele: 5=-CCTG-GACAACATGGTGACACTCG-3=; reverse common: 5=-GTGGGCC-CTGTACTTTTACATC-3=). The conditions used (initial denaturation: 98°C for 20 s; 35 cycles: denaturation 95°C for 30 s, annealing 68°C for 30 s, extension 72°C for 30 s, final extension 72°C for 10 min; melt curve: 95°C for 15 s, 58°C for 15 s, ramp 20 min, 95°C for 15 s) allow for specific PCR products to be synthesized only if the primer is 100% complementary to its template DNA. Real-time PCR was performed on an Eppendorf Realplex 4.0 (Eppendorf North America, Westbury, NY, USA). We were able to verify the validity of merging these data with the data generated from other two platforms by confirming the linkage disequilibrium of this SNP with two other loci across the other two platforms (rs4646343, Sequenom; rs3760188, Illumina). After including this SNP in the data set, the final number of SNPs analyzed was 260 (See Supplemental Fig. S1 for list of SNPs). considered our controls) and 3 groups with increasing levels of hepatic fat accumulation [Ͻ34% (nϭ183; combination of Ͻ5% and 5-33% groups), 34-66% (nϭ118), and Ͼ66% (nϭ60)]. Proportional odds and generalized logit methods were implemented (each allele was assumed to have an additive effect). The generalized logit method was used only if the proportional odds assumption was violated. We built 3 models: model 1 was unadjusted for confounders; model 2 was adjusted for age (Ͻ50 or Ն50), sex, and diabetes diagnosis; and model 3 was adjusted for age, sex, diabetes, and body mass index (BMI). The Benjamini-Hochberg method for false discovery rate (FDR) was used to adjust for multiple tests utilizing the minimum number of independent tests approach or by adjusting for the number of variables tested (see details in figure legends and Ͼ0.95; nϭ225). Model 2 included SNPs that had a raw value of P Ͻ 0.1 in the individual SNP analysis (model 1) minus highly correlated SNPs (nϭ55). The second model was selected to refine steatosis burden predictability and reduce noise from uninformative SNPs. Numbers of clusters in both models were selected by identifying the points at which dissimilarity between clusters substantially increased at each clustering step (measured by the error sum of squares; ref. 17) and by selecting the number of clusters preceding such increase that also provided a large enough sample size. A 2 test and pairwise comparisons were used to compare steatosis burden between clusters. To identify SNPs that distinguished clusters from one another, we evaluated distributions of SNP genotypes between clusters using the 2 test for marginal response homogeneity (likelihood ratio).
Genotypes within cluster 1 that differentiated subjects based on steatosis level were identified with supervised stepwise ordinal logistic regression. The scores for our model were derived by totaling the number of alleles associated with higher steatosis (0, 1, or 2) for the identified SNPs. In some cases, there were no subjects with two copies of the SNP, so the scores were 0 or 1. The scores were weighted depending on whether each allele had an additive effect on steatosis or whether having 0/1 or 1/2 had equivalent effects as determined by the ordinal regression model. If an SNP was associated with higher steatosis and the effects were additive, the scores were 0, 1, or 2 if the subject had 0, 1 or 2 copies of the SNP, respectively. If, on the other hand, having an SNP was associated with lower steatosis, the scores were 2, 1, or 0, if the subject had 0, 1, or 2 copies of the SNP, respectively, since having higher steatosis was associated with having fewer alleles. If having 1 or 2 copies of the SNP was associated with an equivalent effect on higher steatosis, having either 1 or 2 copies received a score of 2, while having 0 copies received a score of 0. If, on the other hand, having 1 or 2 copies of the SNP was associated equivalently with having less steatosis, having 0 copies of the SNP received a score of 2, while having 1 or 2 copies received a score of 0. The sum of alleles for each subject was the assigned score. Table 1 provides the details.
A logistic regression fitting model was used to assess the accuracy of SNP scores to predict steatosis burden. Model discrimination was evaluated using receiver operating curve analysis (Supplemental Fig. S2 ). Analyses were conducted using SAS 9.2 or JMP 8.0 (SAS Institute, Cary, NC, USA).
RESULTS
Population characteristics
Although all subjects who were enrolled in the biorepository were suspected to have NAFLD based on the presence of traditional risk factors, biopsies from 19% showed normal liver histology, and we considered this group our non-NAFLD controls. Characterization of our study population as a whole ( Table 2 ) and by fatty liver groups (Table 3 ) revealed a pattern consistent with what is known about clinical and demographic parameters associated with NAFLD (1). About 1/3 of our cohort consisted of subjects who had biopsies done during bariatric surgery, as opposed to subjects who were seen in the liver clinic. There were notable differences between these two subpopulations (Table  2) , as would be expected based on the criteria for eligibility for bariatric surgery (i.e., morbid obesity or obesity with metabolic complications) and the expected demographics of patients who choose to have bariatric surgery (18) . Specifically, all subjects from the bariatric clinic had BMI Ͼ 34, steatosis was less severe, and there was an overrepresentation of females and African Americans (Table 2) . However, the proportions of case and control subjects were not different (FDR, Pϭ0.3), the diagnosis of NAFLD was made concomitant with bariatric surgery, and, notably, SNP frequency was highly correlated between the two groups (r 2 ϭ0.96; Fig. 2 ). Our purpose was to study the role of genetic variants on hepatic steatosis over a wide range of BMIs because we hypothesize that obesity provides a challenge to hepatic lipid secretion capacity that augments metabolic inefficiencies associated with SNPs. For this reason, we included patients from both clinics to allow us to study a comprehensive spectrum of steatosis and obesity with sufficient power. 
Associations of individual polymorphisms with hepatic steatosis severity
After adjusting for a full complement of confounders, only PNPLA3 rs738409 was significantly associated with increased steatosis burden (FDR, Pϭ0.02; Table 4 ). However, a number of other SNPs did show associations before adjusting for BMI. The APOC3 promoter SNP rs2854117 (T allele) was associated with lower steatosis (model 2; FDR, Pϭ0.04; Table 4 ). We identified 9 novel SNPs in choline/1-carbon metabolism that were associated with lower steatosis (model 2; FDR, P Ͻ 0.05): MTHFR (rs7525338, rs868014), CHDH (rs4563403, rs881883), PEMT (rs8068641, rs7214988), and SLC44A1 (rs10820799, rs440290, rs328006) ( Table 4) . We were unable to confirm the previously reported fatty liver associations of individual SNPs in ADIPOQ rs1501299 (19) , CHDH rs9001 and rs12676 (7), MTHFD1 rs2236225 (8), PEMT rs12325817 (7) and rs7946 (20) , PPARG rs1801282 (21), and STAT3 rs9891119 (22) (FDR, PϾ0.05; not shown).
Steatosis is related to both ethnicity and genotype
African-American individuals are reported to have reduced risk for developing NAFLD (23), making ethnicity a potential confounder in our analysis, and our results confirm this lower incidence (Table 3) . Most of the SNPs with fatty liver associations were differentially distributed in Caucasians and African Americans ( Table 5) . Out of all the SNPs analyzed in this study, 78% were differentially distributed in African Americans vs. Caucasians (PϽ0.05; not shown); the overall lack of correlation in SNP frequency is shown in Fig. 3 (r 2 ϭ0.08). Data from 1000 genomes (24) shows that the discordance in SNP frequency of the SNPs individually associated with steatosis in our study between African Americans and Caucasians is not unique to our study (not shown). Other ethnic groups in 1000 genomes, such as those of Asian and Caribbean descent, do not show the same level of discordance in the SNPs individually associated with steatosis in our study (not shown). Because lower steatosis could be related to both ethnicity and genotype, we did not adjust for ethnicity in any of our models.
Genetic signatures improve prediction of steatosis severity
To determine whether combinations of SNPs that influence hepatic lipid balance are more predictive than single SNPs, we began by asking whether having Variables are shown for the cohort as a whole (nϭ446) and with comparisons between bariatric and liver clinics. Data are presented as median and 25th and 75th percentile or as a percentage. Only African-American and Caucasian ethnicities are compared, since the remaining subjects (nϭ16; 4%) were of several ethnicities, and the cell size was too small to make a useful comparison. AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BP, blood pressure. For continuous measures, Kruskal-Wallis test was used. For categorical variables, Fisher's exact test was used. P values were adjusted for the number of variables tested (nϭ15) using the FDR procedure; values of P Ͻ 0.05 were considered significant. a P vs. non-NAFLD. b P for distribution of steatosis groups.
multiple SNPs in PNPLA3 (the gene most consistently associated with steatosis; ref. 25) was associated with more severe fatty liver. We found that carriers of Ն1 copy of both rs738409 and rs2281135 (nϭ197), when compared to people who had an SNP in only one locus or neither locus (nϭ249), had significantly higher levels of steatosis (Pϭ0.0002; Fig. 4 ).
To investigate whether combinations of SNPs across multiple choline/1-carbon metabolism genes and genes in functionally related pathways might indicate additive metabolic inefficiencies contributing to steatosis risk, we used unsupervised hierarchical clustering to group subjects with similar genotype patterns across all SNPs in our data set (nϭ225; 35 SNPs removed due to high linkage disequilibrium correlation; r 2 Ͼ0.95). On the basis of the criteria for cluster partitioning, 5 clusters were identified (not shown). We then asked whether the genetic signatures that pulled together the clusters had any association with the degree of steatosis. There was an overall difference in level of steatosis across the clusters (Pϭ0.008), with cluster 1 having significantly lower steatosis than all other clusters (PϽ0.007) and the remaining clusters having similar levels of steatosis (not shown).
To improve our ability to distinguish between the SNPs that contributed most to clusters that had subjects with higher steatosis burden, we created a second model containing only SNPs with raw values of P Ͻ 0.1 from the individual SNP association analysis (nϭ55 after removing highly correlated SNPs due to high linkage disequilibrium). Similarity-based cluster partitioning resulted in 5 clusters (Fig. 5 and Supplemental  Fig. S1 ). Overall, the clusters differed significantly in their steatosis burden (Pϭ0.0002; Fig. 6 ). Subjects in cluster 1 were significantly more likely to have a lower steatosis burden than did all the other clusters (PϽ0.007), while those in cluster 2 had a higher steatosis burden than did clusters 3A and 3B (PϽ0.05). Clusters 3A-3C were not significantly different from each other, and we considered them jointly to represent an intermediate amount of steatosis.
We carefully phenotyped the clusters to determine which characteristics coincided with the shared genotype pattern ( Table 6 ). The vast majority of the AfricanAmerican subjects in our study (94%) shared the cluster 1 genotype pattern. Although cluster 1 subjects had the lowest liver fat, they had the highest BMI. Cluster 2 had the highest liver enzyme markers for hepatic damage and elevated triglycerides. Subjects from the liver and bariatric clinics were distributed throughout all 5 clusters. Because clusters 1 and 2 represented the most obvious phenotypic outliers, we focused on defining the SNP patterns of those two clusters, since that would provide the most likely set of candidate SNPs for defining low vs. high steatosis risk. Next, we aimed to define the SNPs that most clearly distinguished clusters 1 and 2. Since clusters were defined by both ethnicity and SNPs, we asked whether cluster 2, which had a similar ethnic distribution as clusters 3A-3C (i.e., primarily Caucasian), had a unique genetic signature. We found that 32 SNPs in ABCB4, CHDH, PEMT, PNPLA3, MTHFR, and SLC44A1 were distributed differentially in cluster 2 vs. clusters 3A-3C (FDR, PϽ0.05; Table 8 ). Notably, the previously reported NAFLDassociated alleles in CHDH rs12676 (7) and PEMT rs7946 (20) , which in our study did not retain statistical significance individually, were enriched in cluster 2 and depleted in cluster 1 (FDR, PϽ0.05).
We found that SNP pattern and being African American were highly correlated, making it difficult to determine whether the lower steatosis seen in cluster 1 was due to SNPs or to another property associated with being African American. To address this, we asked whether SNP patterns within cluster 1 could distinguish the subjects with higher steatosis from those with less disease. Stepwise ordinal regression identified 11 SNPs within cluster 1 that were associated with degree of steatosis (ABCB4 rs31672; APOC3 rs2854117; CHDH 
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Association of SNPs and degree of steatosis was tested across our cohort (n ϭ 446). The SNP is defined by the dbSNP reference SNP (rs) number. Allele change is shown underneath. Region refers to the sequence location: within an exon or intron, upstream (US) or downstream (DS) of the gene (within the 5-kb cutoff for our study), or in the 3= untranslated region (UTR). SNP frequency: proportion of people carrying either 1 or 2 copies of the SNP [(2 ϫ no. of people with 2 copies of SNP) ϩ (1 ϫ no. of people with 1 copy of SNP)/(no. of subjects ϫ 2)]. Model 1, unadjusted for confounders; model 2, adjusted for age (Ͻ50 vs. Ն50), sex, and diabetes diagnosis; and model 3, adjusted for age, sex, diabetes, and BMI. Proportional odds models or generalized logit models were used depending on whether the proportional odds assumption was satisfied (assuming an additive SNP effect). SNPs are organized by raw P value and gene. P values were adjusted for multiple tests utilizing the FDR procedure. The FDR P value was derived by adjusting the raw P value for the number of SNPs tested (nϭ170 after accounting for the minimum number of effective tests); values of P Ͻ 0.05 were considered significant. rs4563403; MTHFR rs7525338; PEMT rs13342397, rs7946, rs8068641, and rs936108; PNPLA3 rs2281135, rs738409; SLC44A1 rs10820799), and they were used to construct a scoring model that summed alleles associated with increased steatosis. We could accurately classify individuals within cluster 1 with higher steatosis based on their SNP score (Pϭ1.0ϫ10
Ϫ10
; Fig. 6, inset) . The receiver operator curve demonstrated that scores from this combination of SNPs discriminated between subjects with high steatosis with a high degree of sensitivity and specificity (area under the curve by steatosis level: Ͻ34%ϭ0.83, 33-66%ϭ0.94, Ͼ66%ϭ0.93; Supplemental  Fig. S2B ).
DISCUSSION
Our study highlights a novel approach to maximize our understanding of how genetic variations influence hepatic steatosis: grouping individuals by shared patterns of SNPs in pathways functionally linked to the phenotype of interest, rather than using traditional single SNP or genome-wide approaches. In the postgenomic era, the identification of individual SNPs that are associated with risk for chronic disease has been disappointing. This is not surprising, given that GWASs usually must make statistical adjustments for testing vast numbers of SNPs (thereby losing power) and because a single gene, much less a single SNP, is unlikely to fully define risk for common complex diseases (2) . In support of this, it is becoming increasingly clear that gene-gene interactions are much more likely to be relevant in defining disease risk, especially between interrelated pathways that influence phenotype (26) . Our approach may become a fundamental first step in identifying epistatic relationships between genes that will allow for stronger hypotheses and increasingly targeted studies. This approach is also highly amenable to studies that merge advanced phenotyping platforms, such as metabolomics, in order to maximize our utilization of genetic signatures to define disease risk. . Synergistic effect on steatosis severity of having SNPs at both rs738409 and rs2281135 in PNPLA3. To assess whether having Ն1 copy of an SNP at both rs738409 and rs2281135 in the PNPLA3 gene was associated with higher steatosis, we used proportional odds models (adjusted for age, sex, diabetes, and BMI as in Table 4 ). Carrying SNPs at both PNPLA3 loci (nϭ197) was associated with higher steatosis burden than carrying an SNP at only one PNPLA3 locus (nϭ249; Pϭ0.0002).
Choline/1-carbon metabolism intersects with pathways that are important for liver function, including lipid/ apolipoprotein and homocysteine (Hcy) metabolism (Fig. 1) , making it plausible that interactions between SNPs across multiple genes may lead to cumulative inefficiencies that contribute to steatosis risk. This is supported by data in humans showing that dietary choline deprivation leads to the development of fatty liver differentially depending on sex and genetic variations in 1-car- Fig. S1 shows a large image of all 5 clusters.) Figure 6 . Steatosis burden can be predicted by clustering subjects by shared SNP patterns, and this prediction can be refined with scoring models that account for the biological association of SNPs on steatosis. Using a 2 test, we first identified an overall difference in steatosis between the 5 clusters generated based on 55 SNPs (Pϭ0.0002). To identify which individual clusters were different, subsequent pairwise comparisons showed that cluster 1 had lower steatosis than all other clusters, cluster 2 had higher steatosis than clusters 3A and 3B, and clusters 3A-3C were not significantly different from each other. Steatosis is defined as non-NAFLD (no histological evidence of fatty liver), Ͻ34%, 34 -66%, Ͼ66%. Inset: given that cluster 1 consisted primarily of AfricanAmerican individuals, we asked whether SNP patterns within cluster 1 could distinguish the subjects with higher steatosis from those with less disease by implementing a scoring model. The model was built by summing the number of alleles associated with higher steatosis for SNPs that were selected due to their association with steatosis within the cluster (see Materials and Methods for full description). Inset shows how the cluster 1 scoring model performed. Discriminatory capacity of the scoring model was evaluated with a logistic fit model and was highly significant (Pϭ1.0ϫ10 Ϫ10 ). *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001. bon genes (6 -8) . A recent publication showed that, in biopsy-characterized postmenopausal women, low choline intake was associated with worse fibrosis (27) , highlighting choline as an important nutrient in NAFLD progression. Our study provides novel insights into the contributions of choline-related SNPs to steatosis severity.
Individual SNPs involved in hepatic steatosis
We confirmed the association between PNPLA3 rs738409 and steatosis severity in a cohort with histologically defined hepatic lipid status (Table 4) . Although PNPLA3 rs738409 is a well-replicated marker of hepatic steatosis, this SNP only explains a small proportion of the risk. Indeed, in our study, 37% of individuals who did not have any degree of steatosis had Ն1 copy of the rs738409 SNP, while 43% of people with any degree of steatosis did not carry this SNP (not shown). Thus, we hypothesized that understanding combinations of shared SNPs in our cohort might give us better information about our phenotype of interest. In support of this notion, we noted an apparent synergism between PNPLA3 rs738409 and rs2281135 SNPs (Fig. 4) . This suggests that measuring both SNPs improves their utility as predictive tools. Interestingly, another PNPLA3 SNP we genotyped, rs6006460, which has been reported to be common in African Americans and associated with decreased risk for NAFLD (25) , was not found to be polymorphic in this population and thus had no effect on steatosis risk. PNPLA3 is a phospholipase A2 family member that hydrolyzes glycerolipids, including PtdCho, in vitro (28) and also has been shown to promote lipid synthesis due to its function as a lysophosphatidic acid acyltransferase (29) . Given the involvement of PNPLA3 in the metabolism of cholinecontaining phospholipids, deciphering the crosstalk between PNPLA3 and choline/1-carbon metabolism may result in a deeper understanding of the mechanisms regulating hepatic lipid balance.
Excess lipid influx coupled with genetically defined diminished lipid export synergistically influence hepatic lipid burden
Accumulation of fat in the liver is a function of the balance between lipid input (driven largely by excess calorie intake) and the rate of lipid output (mainly as VLDL; Fig. 1 ). Obesity and hepatic steatosis frequently occur in the same individuals because the inputs to hepatic lipid production are increased, thereby challenging the capacity of liver to secrete lipids. Indeed, excess caloric intake is one important cause of increased rates of formation of hepatic triglycerides, and reduction in intake has been shown to diminish hepatic lipid burden (30) . Choline metabolism is essential for the export of hepatic lipids, since its metabolite, PtdCho, is necessary for VLDL formation. Choline deficiency in humans and mice is associated with increased hepatic lipid stores. Although obesity is generally associated with higher steatosis (1), this is not the case in all individuals, and this may be because of differential capacity to secrete lipid due to metabolic inefficiencies caused by SNPs in choline and 1-carbon metabolism. In addition, some individuals may reach a threshold BMI in which lipid input is severely increased, and genetic contributions may become irrelevant. Table is similar to Table 3 , except the variables were compared between clusters generated from shared genotypes ( Fig. 5 and Supplemental  Fig. S1 ). FDR adjustment for multiple comparisons was based on the number of variables tested (nϭ14). Data are presented as median and 25th and 75th percentile or as a percentage. BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BP, blood pressure.
Genetic signatures are associated with steatosis severity and may provide insight into disease disparities
The major finding in this study is that an unsupervised hierarchical clustering approach revealed patterns of SNPs across multiple functionally relevant genes that were highly associated with steatosis burden. Our approach defined SNP signatures, based on the number of copies of SNP alleles carried across a panel of 55 SNPs, which were associated with steatosis severity in specific groups of people that share other characteristics, such as ethnicity and biochemical indicators of NAFLD (Figs. 5 and 6 ). The genetic signatures that we identified span pathways that are known to be mechanistically related to NAFLD (Fig. 1) . This supports our hypothesis that additive metabolic inefficiencies, driven at least in part by SNP patterns, contribute to steatosis severity.
Among the multiple choline/1-carbon genes we identified that defined low vs. high steatosis burden (Tables 7 and 8 ), many have biologically plausible links to hepatic steatosis. For example, we found that SNPs in CHDH and PEMT were associated with steatosis, and this is in agreement with previous studies (7, 20) . We also uncovered SNPs in several genes not previously linked to steatosis, including ABCB4, MTHFR, and SLC44A1. ABCB4 encodes for an enzyme that flips PtdCho from the inner to the outer hepatocyte canalicular membrane, so that this phospholipid is available for incorporation into bile micelles (31) . Bile salts can act as signaling agents that modulate glucose and energy metabolism (32), and our observations suggest that this metabolic pathway, and its intersection with choline/1-carbon metabolism, should be explored further as a modulator of NAFLD. Recently, Abcb4 was shown to modulate glucose metabolism in mice, likely via a PtdCho-dependent pathway, and ABCB4 SNPs in humans were also associated with glucose levels (33) . This novel metabolic link to ABCB4 strengthens the biological plausibility of our findings and also suggests that this gene needs to be studied further in the context of metabolic disease. MTHFR is important for the formation of methionine via the remethylation of Hcy. Functional SNPs in this gene have been linked to elevated Hcy (34) and central adiposity (35) , and both of these mechanisms could underlie a functional role of MTHFR in steatosis. The use of choline as a methyl group donor requires conversion of choline to betaine in the mitochondria (36) . SLC44A1 is a plasma membrane and mitochondrial choline transporter (37) . SNPs in the gene could impair choline's entry into mitochondria, potentially influencing choline availability. Our results suggest that choline/1-carbon and functionally interrelated pathways should be investigated further to better define their role in hepatic steatosis and to determine whether nutritional interventions might be beneficial.
The SNPs that encompassed the signatures for high vs. low steatosis included genes with functional roles in hepatic steatosis beyond those associated directly with choline metabolism. One notable example is APOC3. The rs2854117 SNP has previously been associated with hepatic steatosis, although subsequent publications were unable to replicate the original finding. In our study, an association is seen with the C allele, not the T allele, which is different from the original finding Table is similar to Table 7 , except the distribution of SNP used to generate clusters (nϭ55) was compared in cluster 1 vs. the rest of the clusters.
( Tables 4 and 8 and ref. 38) and implies a protective effect of the SNP. APOC3 is a major constituent of VLDL and inhibits lipoprotein lipase. The rs2854117 T allele abolishes insulin-mediated down-regulation of the gene, leading to elevated levels of APOC3 and triglycerides (39) . In mice, overexpression of ApoC3 promotes hepatic steatosis (40) . Because the T allele is responsible for the detrimental gain of function of APOC3, it is difficult to explain why it appears protective in our study. Obesity has been identified as a factor that modulates observed effects of APOC3 SNPs, and perhaps this is playing a role in our study (41) . Furthermore, two other studies have identified a weak effect in the same direction as our results with an SNP that is in linkage disequilibrium with the one we measured (rs2854116; refs. 42, 43) . It is reasonable to expect altered VLDL metabolism via APOC3 to be involved in steatosis, possibly through mechanisms involving 1-carbon metabolism, and more studies are needed to clarify the potential role of this gene in hepatic steatosis. Other examples of genes with functional links to 1-carbon metabolism, which were associated with steatosis in our clustering algorithm, include SCD and FADS2, both of which are involved in lipid metabolic processes with relevance to NAFLD (44 -47) .
The fact that clustering unmasked the association of SNPs that have previously been functionally linked with steatosis (e.g., CHDH rs12676 and PEMT rs7946; refs. 7, 20) but did not show effects individually, suggests that stratifying cohorts into groups of people with shared SNPs helps to reveal the subsets of individuals for whom particular SNPs are important. If our approach can be replicated and refined, it may prove instrumental in understanding why many SNPs with disease associations are often not replicated in subsequent studies. In support of this, a GWAS by Speliotes et al. (48) , published after the conclusion of our studies, identified several SNPs to be associated with NAFLD in addition to PNPLA3. In that study, some of the identified SNPs had distinct effects on metabolic traits that are common in individuals with NAFLD. They concluded that hepatic steatosis is not uniformly influenced by dysfunction in metabolic traits, such as glucose metabolism and obesity, and that understanding functional SNP clustering could prove valuable for defining metabolic heterogeneity in the etiology of hepatic steatosis. Our findings are concurrent with their conclusions, and the SNPs identified in their study should be included in future studies aimed at understanding gene-gene interactions in NAFLD. Previous attempts to assess the combined effects of SNPs in complex diseases have been only marginally successful (49, 50) , perhaps because those approaches, which were based mainly on SNPs with reported disease associations from GWASs, missed the subtle cumulative effect of SNPs that we identified with our hypothesis-driven, cluster-defined approach.
We identified an SNP signature that clustered most of the African-American subjects, and they had much less steatosis than would be expected for a given BMI. This is in agreement with previous reports of lower incidence of NAFLD in African Americans (23) . We hypothesize that this genotype difference, and the likely alteration in choline/1-carbon metabolism, helps to explain the apparent protection from steatosis. This is supported by other studies that have identified differences in energy expenditure (51) and choline status (52) in African Americans. Utilizing a scoring model, where we summed the SNP alleles associated with higher steatosis, we could identify the subgroup of individuals within cluster 1, who had high, not low, steatosis. This specific 11-SNP score could be useful for identifying African-American individuals who deviate from the expected low steatosis risk and are in need of more aggressive interventions. It is also possible that this signature can identify African-American individuals with greater risk of liver disease progression, and this warrants further study. In the remaining population, which was composed primarily of Caucasian subjects, the SNP pattern within cluster 2 was able to distinguish high vs. intermediate levels of hepatic steatosis (clusters 3A-3C). Therefore, the 55-SNP signature also may be quite useful for identifying high-risk Caucasian individuals. A similar clustering approach recently demonstrated that gene expression patterns in breast tumors segregated subjects into clusters almost perfectly by ethnicity (53) , suggesting that there are key metabolic differences that are related to both ethnicity and disease status. In addition, despite having a lower incidence of NAFLD, African Americans have a higher risk of HCC than Caucasians. A recent study found that African Americans have a very high prevalence of an SNP in the epidermal growth factor receptor that is associated with higher HCC risk (54) . This study highlights that ethnically defined genetic differences can also be relevant for phenotype. Our findings suggest that metabolic inefficiencies revealed by SNP patterns in choline/1-carbon genes, and not another property of ethnicity, underlie the differential steatosis burden identified by our clustering algorithm.
Strengths and limitations
A major strength of our study is the availability of liver biopsies, the gold standard in defining hepatic lipid burden, in both case and control subjects. This allowed us to map the contribution of SNPs to steatosis across a comprehensive spectrum of disease burden. Another strength is the validation of previous SNPs with individual effects on hepatic steatosis, which both confirms the role of those SNPs and supports the validity of our experimental design. One key feature of this study that allowed for meaningful results was the inclusion of SNPs across pathways known to be relevant for NAFLD physiology (Fig. 1) . This hypothesis-driven approach allowed a focused, yet in-depth study, of the genetic contribution of 1-carbon/choline pathways to steatosis. Our unique method for utilizing SNP data to understand the risk of complex disease may prove to be quite useful, since a single SNP is not sufficient to define a phenotype in all individuals and the role of SNPs may be mitigated by the presence or absence of other SNPs. Notably, our approach may help clarify the often contradictory SNP association data reported in the literature, since it helps to define the specific subgroups within a population for whom disease-causing alleles may be most important.
Our study also has several limitations. Given that this is the first study to attempt SNP-based clustering to interrogate NAFLD phenotypes, validation studies are necessary. In future studies, we will genotype multiple ethnically and phenotypically diverse cohorts with welldefined NAFLD to provide sufficient power for training and validation sets. This will allow us to better define clusters, remove uninformative SNPs, add SNPs to our panel that improve predictive power and better understand genetic differences with functional implications in different ethnic groups. The exact function of all the SNPs identified in our panel is not known. However, we designed our study with specific hypotheses related to pathways that are relevant for hepatic steatosis and designed our SNP selection approach to maximize inclusion of functional variants. Indeed, bioinformatic analyses identified that 51% of the SNPs included in our final clustering model are in regions with regulatory potential (not shown). In addition, SNPs without obvious functional implications might be quite important for human disease, and this is highlighted in a recent study in which the authors found that synonymous SNPs and SNPs in the 3= untranslated region (UTR) of genes are highly likely to be involved in disease mechanisms and should be investigated further (55) . These factors, and the fact that SNP patterns were highly associated with phenotype, suggest that the genetic signatures that we identified may be functionally relevant. Once SNP patterns are validated, future studies will utilize metabolomics analyses to define how the SNP patterns are associated with flux through specific metabolic pathways. This will allow us to identify disease-relevant metabolic inefficiencies that are potentially amenable to nutritional or pharmacological interventions. Although the inclusion of subjects from both a bariatric and liver clinic may be viewed as a limitation due to the differences between these groups, this heterogeneity was not a factor in the unsupervised cluster analysis since the SNPs did not group individuals by clinic. We also note that other studies assessing genetic variants in hepatic disease also combined similar groups of individuals (43, 56) . A key element that needs to be considered in future studies is the role of diet in revealing SNP-mediated metabolic inefficiencies. Finally, our study was limited to hepatic steatosis, and studies are in progress to address whether our approach could be useful for characterizing genetic factors associated with advanced liver disease.
CONCLUSIONS
The understanding of genetic polymorphisms and disease risk is rapidly developing, and we have demonstrated the value of utilizing unsupervised hierarchical clustering to gain additional insight into genetic variants that are associated with steatosis in well-phenotyped subjects. Our approach may bring us one step closer to personalized medicine by allowing individuals within a cohort to be stratified by SNP patterns to better understand disease risk. If the utility of the genetic signatures identified in this work can be replicated and refined, it could provide a noninvasive mechanism to improve the risk stratification currently achieved with traditional clinical biomarkers.
